These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24712857)

  • 61. An update on the use of lenalidomide for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
    Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
    Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
    Iino M
    Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829
    [No Abstract]   [Full Text] [Related]  

  • 65. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
    Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
    Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
    [No Abstract]   [Full Text] [Related]  

  • 66. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases.
    Janols H; Bergenfelz C; Allaoui R; Larsson AM; Rydén L; Björnsson S; Janciauskiene S; Wullt M; Bredberg A; Leandersson K
    J Leukoc Biol; 2014 Nov; 96(5):685-93. PubMed ID: 24929004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.
    Kalathil S; Lugade AA; Miller A; Iyer R; Thanavala Y
    Cancer Res; 2013 Apr; 73(8):2435-44. PubMed ID: 23423978
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The major CD8 T cell effector memory subset in the normal and Chlamydia trachomatis-infected human endocervix is low in perforin.
    Ibana JA; Myers L; Porretta C; Lewis M; Taylor SN; Martin DH; Quayle AJ
    BMC Immunol; 2012 Dec; 13():66. PubMed ID: 23216954
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
    Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
    Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 71. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 74. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
    Maïga S; Gomez-Bougie P; Bonnaud S; Gratas C; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
    Br J Cancer; 2013 May; 108(9):1801-6. PubMed ID: 23632478
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.
    Fostier K; Caers J; Meuleman N; Broos K; Corthals J; Thielemans K; Schots R; De Keersmaecker B
    Oncotarget; 2018 Apr; 9(29):20476-20489. PubMed ID: 29755666
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
    Kuroda J; Kobayashi T; Taniwaki M
    Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mechanism of action of immunomodulatory agents in multiple myeloma.
    Reske T; Fulciniti M; Munshi NC
    Med Oncol; 2010 Jun; 27 Suppl 1(Suppl 1):S7-13. PubMed ID: 20405248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.